|
![]() |
|||
|
||||
OverviewThis is the first book to examine how effectively American and supranational EU governments have regulated innovative pharmaceuticals during the last 30 years regarding public health. It explains why pharmaceutical regulation has been misdirected by commercial interests and misconceived ideologies. Full Product DetailsAuthor: C. Davis , J. Abraham , Abraham , Paul Davis, HaroldPublisher: Palgrave Macmillan Imprint: Palgrave Macmillan Dimensions: Width: 14.00cm , Height: 1.70cm , Length: 21.60cm Weight: 5.219kg ISBN: 9780230008663ISBN 10: 0230008666 Pages: 321 Publication Date: 08 November 2013 Audience: Professional and scholarly , Professional & Vocational Format: Hardback Publisher's Status: Active Availability: Awaiting stock ![]() The supplier is currently out of stock of this item. It will be ordered for you and placed on backorder. Once it does come back in stock, we will ship it out for you. Table of Contents1. Putting Pharmaceutical Regulation to the Test: A Social Science for Public Health 2. The Political Economy of 'Innovative' Drug Regulation in the Neo-Liberal Era 3. Designs on Diabetes Drugs 4. Desperate Regulation for Desperate Cancer Patients 5. The Making of a Harmful 'Therapeutic Breakthrough' 6. The Regulatory Science and Politics of Risk Management 7. Conclusions and Policy ImplicationsReviewsPrecisely 50 years have passed since the first truly modern system of medicines regulation came into operation in The Netherlands. That is a good reason to take stock of what drug regulation has achieved in half a century, and where it has perhaps failed to serve society optimally. Courtney Davis and John Abraham have now done precisely that, in a thoughtful and independent study of developments on both sides of the Atlantic. Their findings make clear the extent to which empty rhetoric from every direction (emanating most loudly from industry's puppet organizations and from neo-liberal politicians or think tanks) has been allowed to dominate the debate. This book is so solidly documented that it does not make for easy reading, but that reading will be rewarded. If in the coming years society is to rethink these matters, to identify truly valid interests in the pharmaceutical field, and to strike a fair balance betweenthem, with the genuine needs of the individual consumer and patient ever in the foreground, this is the way to do it. - Graham Dukes, External Professor of Drug Policy Studies, University of Oslo, Norway Davis and Abraham provide new insights into how the neo-liberal regime that has developed since the 1980s has profoundly biased the way the Food and Drug Administration and the European Medicines Agency deal with drug approvals and safety, to the detriment of the patients they are supposed to be protecting. The drug companies, not the people who need effective and safe medicines, are now the primary clients of drug regulators. However, Davis and Abraham do not stop with just criticizing the current situation; they offer concrete steps that can be taken to restore drug regulation to what should be its true function. This book should be the starting point for anyone interested in understanding the forces that are shaping the medicines we take.- Joel Lexchin, Professor of Health Policy, York University, Canada Author InformationCourtney Davis is Senior Lecturer in Sociology at Kings College London, UK. Previously Director of the Centre for Corporate Accountability, she is author of Making Companies Safe. John Abraham is Professor of Sociology at Kings College London, UK. Author of over 100 publications on pharmaceuticals in society, he was Special Expert Adviser to the UK House of Commons Health Select Committee Inquiry into the influence of the pharmaceutical industry (2005). Tab Content 6Author Website:Countries AvailableAll regions |